Date: Thu, 18 Dec 1997 14:52:32 GMT
Server: Stronghold/1.3.4 Ben-SSL/1.3 Apache/1.1.3
Content-type: text/html
Content-length: 13195
Last-modified: Mon, 06 Oct 1997 14:20:16 GMT

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Publications</TITLE>
<META NAME="Author" CONTENT="Nancy Everett">
<META NAME="Generator" CONTENT="NetObjects Fusion 2.0.1 for Windows">

</HEAD>

<BODY BGCOLOR="#0000FF" LINK="#FFFFFF" VLINK="#FF80C0" TEXT="#FFFFFF">

  <TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=681>
   <TR VALIGN="top" ALIGN="left">
	<TD WIDTH=72 HEIGHT =31><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =72 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=5><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =5 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=1><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =1 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=145><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =145 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=200><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =200 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=7><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =7 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=124><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =124 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=127><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =127 HEIGHT =1 BORDER=0></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD HEIGHT =95></TD>
	<TD WIDTH=482 COLSPAN=6 ALIGN="left" VALIGN="top"><IMG HEIGHT=80 WIDTH=440 SRC="../assets/images/banner1_copy.JPG"  BORDER=0  ALT="Picture" ></TD>
	<TD></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD COLSPAN=2 HEIGHT =37></TD>
	<TD WIDTH=353 COLSPAN=4><P><B><FONT COLOR="#00FFFF" SIZE="+2" FACE="ITC Officina Sans Book">Scientific Publications</B></FONT></TD>

	<TD COLSPAN=2></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD COLSPAN=8 HEIGHT =11></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD COLSPAN=3 HEIGHT =2391></TD>
	<TD WIDTH=476 COLSPAN=4><P><FONT FACE="Modern">“Cross Clade (B,C and E Subtypes) HIV Consensus Sequence Recognition by Antibodies Based on a p17 (SF2) Synthetic Peptide” D. ZIMMERMAN, J.P. LLOYD, M.D. WINSHIP and P.S. SARIN 9th Annual Meeting National Cooperative Vaccine Development Group Bethesda MD May 1997.</FONT></P><P><FONT FACE="Modern">“Modified HGP-30 Incorporated into a Peptide Heterconjugate: A Novel Approach in HIV Vaccine Development”. D. ZIMMERMAN, J. P. LLOYD, M.D. WINSHIP and P.S. SARIN Washington DC 4th Retrovirus Meeting Jan 1997.</FONT></P><P><FONT FACE="Modern">“Immune Responses in Peripheral Blood Lymphocytes Induced by Immunizations with HIV-1 P17 Vaccine (HGP-30) Protect Scid Mice from HIV-1 Infection” J. KAHN, J.E. TALMADGE</FONT><FONT SIZE="-2" FACE="Modern">,</FONT><FONT FACE="Modern"> H.GENDELMAN, S. BECKNER, M.D. WINSHIP, P.S. SARIN, P. HESELTINE. UCSF, San Francisco, CA; U. Nebraska, Omaha, NE; CEL-SCI Corporation, Alexandria, VA; USC, Los Angeles, CA. XI th International Conference on AIDS, Vancouver, B.C. July 11, 1996.</FONT></P><P><FONT FACE="Modern">&quot;The use of peptide heteroconjugates to prime TH1 associated antibodies (IgG2a) directed against an epitope (38.G) of Mycobacterium tuberculosis which recognize the epitope in the 38KD protein.&quot;; Zimmerman, D.H., Morris, S., Rouse, D., Worthington, K.F.W., Elliott, D.A., Rosenthal, K.S.; May 1996, ASM New Orleans, LA.<BR></FONT>&nbsp;</P><P><FONT FACE="Modern">&nbsp;&quot;Immunization with Peptide Heteroconjugates Primes a TH1 Associated Antibody (IgG2a) Response which Recognizes the Native Epitope on the 38 kDa Protein of Mycobacterium tuberculosi.&quot;; Zimmerman, D.H., Morris, S., Rouse, D., Worthington, K.F.W., Elliott, D.A., and Rosenthal, K.S.; Vacc. Res., 1996, 5:103-118.<BR></FONT>&nbsp;</P><P><FONT FACE="Modern">&nbsp;&quot;A New Approach to T Cell Activation: Natural and Synthetic Conjugates Capable of Activating T Cells.&quot;; Zimmerman, D.H., Bergmann, K.F., Rosenthal , K.S., and Elliott, D. A. ; Vacc. Res., 1996, 5:91-102.<BR></FONT>&nbsp;</P><P><FONT FACE="Modern">&nbsp;&quot; HIV-1 p17 synthetic peptide vaccine HGP-30: Induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.&quot;; Sarin, P.S., Mora, C.A., Naylor, P.H., Markham, R., Schwartz, D., Kahn, J., Heseltine, P., Gazzard, B., Youle, M., Rios, A., and Goldstein, A.L.; Cellular and Molec. Biol., 1995, 41 (3): 401-407.<BR>&nbsp;</FONT></P><P><FONT FACE="Modern">&quot;Leukocyte Interleukin, Injection (LI) augmentation of natural killer cells and cytolytic T-lymphocytes.&quot;; Chirigos, M.A., Talor, E., Sidwell, R.W., Burger, R.A., and Warren, R.P.; Immunopharm. and Immunotox., 1995, 17(2): 247.<BR>&nbsp;</FONT></P><P><FONT FACE="Modern">&quot;The use of peptide heteroconjugates to prime TH1 or TH2 activity to an epitope of Mycobacterium tuberculostis.&quot;; Zimmerman, D., Rosenthal, K. and Elliott, D. 1995, ICAAC, San Francisco, CA.<BR>&nbsp;</FONT></P><P><FONT FACE="Modern">&quot;Cytotoxic and humoral immune responses to HIV-1 p17 synthetic peptide HGP-30 in human volunteers.&quot;; Sarin, P.S., Markham, R., Schwartz, D., Naylor, P.H., Kahn, J., Heseltine, P., Gazzard, B., Youle, M., Rios, A., and Goldstein, A.L.; Vacc. Res., 1994, 3: 49-57.<BR>&nbsp;</FONT></P><P><FONT FACE="Modern">&quot;Interleukins and contrasuppression induce immune regression of head and neck cancer.&quot;; Hadden, J.W., Endicott, J., Baekey, P., Skipper, P. and Hadden, E.M.: Arch. Otolar. Head Neck Surg.; 1994, 120: 395-403.<BR>&nbsp;</FONT></P><P><FONT FACE="Modern">&quot;A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue subunit vaccine in seronegative subjects.&quot;; Kahn, J.D., Stites, D.P., Scillian, J.T., Murcar, N., Stryker, R., Volberding, P.A., Naylor, P.H., Goldstein, A.L., Sarin, P.S., Simmon, V.F., Wang, S.S. and Heseltine, P.; AIDS Res. Hum. Retroviruses, 1992, 8: 1321-1325.<BR>&nbsp;</FONT></P><P><FONT FACE="Modern">&quot;Presence of specific antibodies to synthetic epitopes of HIV-1 gag p17 correlates with stages of HIV-1 infection in homosexuals and IV drug abusers.&quot;; Jiang, J.D., Chu, F.N., Naylor, P.H., Kirkley, J.E., Mandeli, J., Wallace, J.I., Sarin, P.S., Goldstein, A.L., Holland, J.F. and Bekesi, J.G.; J. AIDS, 1992, 5: 382-390.<BR>&nbsp;</FONT></P><P><FONT FACE="Modern">&quot;Safety and immunogenicity of HGP-30: Evaluation of a synthetic HIV-1 p17 vaccine in healthy HIV seronegative volunteers.&quot;; Gazzard, B., Youle, M., MacDonald, V., O'Toole, C.M. , Stambuk, D., Rios, A., Achour, A., Zagury, D., Naylor, P.H., Sarin, P.S., and Goldstein, A.L.; Vacc. Res., 1992, 1: 129-135.<BR></FONT>&nbsp;</P><P><FONT FACE="Modern">&nbsp;&quot;Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17 based synthetic peptide AIDS vaccine HGP-30/KLH.&quot;; Naylor, P.H., Sztein, M.B., Wada, S., Maurer, S., Hilterman, D., Kirkley, J.E., Naylor, C.W., Zook, B.C., Hitzelberg, R.A., Gibbs, C.J., Zagury, D., Achour, A., O'Toole, C., Gazzard, B., Youle, M., Rios, A., Sarin, P.S. and Goldstein, A.L.; Int. J. Immunopharm., 1991, 13 (suppl. 1): 117-127.<BR>&nbsp;</FONT></P><P><FONT FACE="Modern">&quot;Diagnostic assays for human immunodeficiency virus infection and for clinical progression by use of synthetic p17 peptide epitopes.&quot;; Naylor, P.H., Heithaus, A., Kale, A., Erdos, R., Kirkley, J., and Goldstein, A.L.; Monogr. Virol., 1990, 18: 74-90.<BR>&nbsp;</FONT></P><P><FONT FACE="Modern">&quot;HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17 is a target for cytotoxic lymphocytes in HIV infected individuals.&quot;; Achour, A., Picard, D., Zagury, D., Sarin, P.S., Gallo, R.C., Naylor, P.H., and Goldstein, A.L., Proc. Natl. Acad. Sci. U.S.A., 1990, 87: 7045-7049.<BR></FONT>&nbsp;</P><P><FONT FACE="Modern">&nbsp;&quot;Adoptive immunotherapy administered via the hepatic artery and intralesional interleukin-2 in hepatocellular carcinoma.&quot;; Fagan, E.A., Pulley, M., Limb, A., Wolstencroft, R., Cranenburgh, C., De Vinci, C., Karani, J., Michell, M., Nunnerley, H., Zaman, S., Pizza., G., Dumonde, D., and Williams, R.; Canc. Treatm. Rev., 1989 (Supp. A), 151-160.<BR></FONT>&nbsp;</P><P><FONT FACE="Modern">&nbsp;&quot;Intravenous, intralesional and endolymphatic administration of lymphokines in human cancer.&quot;; Pulley, M.S., Nagendran, V., Edwards, J.M., and Dumonde, D.C.; Lymph. Res., 1986, Vol. 5 (Supp. 1).</FONT></P><P>&nbsp;</P><P>&nbsp;</TD>

	<TD></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD COLSPAN=8 HEIGHT =22></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD COLSPAN=4></TD>
	<TD WIDTH=200><P ALIGN="CENTER"><FONT COLOR="#FFFFFF" SIZE="-1" FACE="Modern">66 Canal Center Plaza Suite 510<BR>&nbsp;Alexandria VA 22314<BR>&nbsp;USA<BR>&nbsp;Telephone: 703-549-5293<BR>&nbsp;Facsimile:&nbsp; 703-549-6269</FONT></TD>

	<TD COLSPAN=3></TD>
   </TR>
  </TABLE>

  <TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=681>
   <TR VALIGN="top" ALIGN="left">
	<TD WIDTH=52 HEIGHT =20><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =52 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=589><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =589 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=40><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =40 HEIGHT =1 BORDER=0></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD></TD>
	<TD WIDTH=589><P><A HREF="../welcome.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Home</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp; </FONT><A HREF="../html/publications.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Publications</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp;&nbsp; </FONT><A HREF="../html/mission.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Mission</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp;&nbsp; </FONT><A HREF="../html/_shareholder_letter.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Shareholder Letter</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp;&nbsp; </FONT><A HREF="../html/product_chart.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Product Chart</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp;&nbsp;&nbsp; </FONT><A HREF="../html/basics.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Basics</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp;&nbsp;&nbsp; </FONT><A HREF="../html/questions.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Questions</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp;&nbsp;&nbsp; </FONT><A HREF="../html/corporate.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Corporate</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp;&nbsp;&nbsp; </FONT><A HREF="../html/investor.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">FY96</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica">&nbsp;&nbsp;&nbsp;&nbsp; </FONT><A HREF="../html/employment.htm"><FONT SIZE="-2" FACE="Arial,Helvetica">Employment</FONT></A><FONT SIZE="-2" FACE="Arial,Helvetica"></FONT></TD>

	<TD></TD>
   </TR>
  </TABLE>

  <TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=681>
   <TR VALIGN="top" ALIGN="left">
	<TD WIDTH=128 HEIGHT =320><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =128 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=55><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =55 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=96><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =96 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=68><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =68 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=334><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =334 HEIGHT =1 BORDER=0></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD COLSPAN=2 HEIGHT =57></TD>
	<TD WIDTH=96 ROWSPAN=2>
	  <TABLE BORDER=0 CELLSPACING=0 CELLPADDING=3 >
	 <TR VALIGN="top" ALIGN="left">
		<TD WIDTH=90 HEIGHT=90><A HREF="../welcome.htm"><IMG HEIGHT=90 WIDTH=90 SRC="file:///"  BORDER=0  ALT=" Home " ></A></TD>
	 </TR>
	  </TABLE></TD>
	<TD COLSPAN=2></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD HEIGHT =39></TD>
	<TD WIDTH=219 COLSPAN=3 ROWSPAN=2><P ALIGN="CENTER"><FONT COLOR="#FFFFFF" SIZE="-1" FACE="Modern">66 Canal Center Plaza Suite 510<BR>&nbsp;Alexandria VA 22314<BR>&nbsp;USA<BR>&nbsp;Telephone: 703-549-5293<BR>&nbsp;Facsimile:&nbsp; 703-549-6269</FONT></TD>

	<TD></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD HEIGHT =48></TD>
	<TD></TD>
   </TR>
  </TABLE>

  <TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=681>
   <TR VALIGN="top" ALIGN="left">
	<TD WIDTH=113 HEIGHT =20><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =113 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=284><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =284 HEIGHT =1 BORDER=0></TD>
	<TD WIDTH=284><IMG SRC="../assets/auto_generated_images/img_39325fe5.gif" WIDTH =284 HEIGHT =1 BORDER=0></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD HEIGHT =30></TD>
	<TD WIDTH=284><P><A HREF="http://everettcd.com"><FONT SIZE="-1" FACE="Modern">site designed and hosted by everettcd.com</FONT></A><FONT SIZE="-1" FACE="Modern"></FONT></TD>

	<TD></TD>
   </TR>
   <TR VALIGN="top" ALIGN="left">
	<TD COLSPAN=3 HEIGHT =468></TD>
   </TR>
  </TABLE>
</BODY>
</HTML>
